1. Home
  2. ETNB vs TXO Comparison

ETNB vs TXO Comparison

Compare ETNB & TXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
  • TXO
  • Stock Information
  • Founded
  • ETNB 2018
  • TXO 2012
  • Country
  • ETNB United States
  • TXO United States
  • Employees
  • ETNB N/A
  • TXO N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • TXO Oil & Gas Production
  • Sector
  • ETNB Health Care
  • TXO Energy
  • Exchange
  • ETNB Nasdaq
  • TXO Nasdaq
  • Market Cap
  • ETNB 864.2M
  • TXO 692.7M
  • IPO Year
  • ETNB 2019
  • TXO 2023
  • Fundamental
  • Price
  • ETNB $6.31
  • TXO $19.32
  • Analyst Decision
  • ETNB Buy
  • TXO Strong Buy
  • Analyst Count
  • ETNB 7
  • TXO 2
  • Target Price
  • ETNB $30.33
  • TXO $26.00
  • AVG Volume (30 Days)
  • ETNB 1.3M
  • TXO 126.0K
  • Earning Date
  • ETNB 02-27-2025
  • TXO 03-04-2025
  • Dividend Yield
  • ETNB N/A
  • TXO 12.27%
  • EPS Growth
  • ETNB N/A
  • TXO N/A
  • EPS
  • ETNB N/A
  • TXO N/A
  • Revenue
  • ETNB N/A
  • TXO $285,451,000.00
  • Revenue This Year
  • ETNB N/A
  • TXO N/A
  • Revenue Next Year
  • ETNB N/A
  • TXO $28.33
  • P/E Ratio
  • ETNB N/A
  • TXO N/A
  • Revenue Growth
  • ETNB N/A
  • TXO N/A
  • 52 Week Low
  • ETNB $5.99
  • TXO $15.22
  • 52 Week High
  • ETNB $16.63
  • TXO $23.56
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 31.27
  • TXO 76.20
  • Support Level
  • ETNB $5.99
  • TXO $16.49
  • Resistance Level
  • ETNB $6.65
  • TXO $17.41
  • Average True Range (ATR)
  • ETNB 0.40
  • TXO 0.67
  • MACD
  • ETNB -0.14
  • TXO 0.29
  • Stochastic Oscillator
  • ETNB 15.70
  • TXO 95.17

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About TXO TXO Partners L.P.

TXO Partners LP is focused on the acquisition, development, optimization and exploitation of oil, natural gas, and natural gas liquid reserves in North America.

Share on Social Networks: